Pregabalin in partial seizures: a pragmatic 21-week, open-label study (PREPS).

@article{Ryvlin2010PregabalinIP,
  title={Pregabalin in partial seizures: a pragmatic 21-week, open-label study (PREPS).},
  author={Philippe Ryvlin and Reetta K{\"a}lvi{\"a}inen and F Von Raison and Salvatore Giordano and Birol Emir and Krai Chatamra},
  journal={European journal of neurology},
  year={2010},
  volume={17 5},
  pages={
          726-32
        }
}
BACKGROUND AND PURPOSE Pregabalin has demonstrated efficacy in controlled trials as adjunctive treatment in patients with refractory seizures. METHODS This open-label, 21-week study in adults with at least two partial seizures in the last 2 months, who were inadequately controlled with one to three antiepileptic drugs, evaluated pregabalin 150-600 mg/day (dosed twice daily). The study comprised a prospective or retrospective 8-week baseline phase, and 9-week dose optimization and 12-week… CONTINUE READING
BETA